Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Issue 14 (6th December 2019)

• Record Type: Journal Article
• Authors: Bashir, Qaiser; Chamoun, Kamal; Milton, Denái R.; Khan, Maliha; Ahmed, Sairah; Mehta, Rohtesh; Popat, Uday R.; Kebriaei, Partow; Nieto, Yago; Oran, Betul; Ciurea, Stefan O.; Hosing, Chitra; Khouri, Isa; Patel, Krina; Manasanch, Elisabet E.; Lee, Hans C.; Orlowski, Robert Z.; Champlin, Richard E.; Qazilbash, Muzaffar H.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 14(2019)
• Page Start: 3536
• Page End: 3543
• Publication Date: 2019-12-06
• Subjects: Clinical results -- marrow and stem cell transpantation -- myeloma -- neoplasia -- elderly; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1633633
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: There is limited data on the outcomes of autologous hematopoietic cell transplantation (auto-HCT) in myeloma patients, 75 or older. We retrospectively analyzed all myeloma patients ( n = 72), aged ≥75, who underwent auto-HCT at our center between January 1, 2000, and December 31, 2015. All patients received melphalan ≥140 mg m −2 conditioning. At day-100, the cumulative incidence of non-relapse mortality was 1%. The overall response rate was 91% with 29% achieving complete/stringent complete remission. The median progression-free survival (PFS) was 31.4 months, and median overall survival (OS) was 72.8 months. The presence of high-risk cytogenetic abnormalities was associated with inferior PFS ( p = 0.005) and OS ( p = 0.005), while international staging system stage III was identified as a negative prognostic factor for OS ( p = 0.002 vs. stage II). We conclude that auto-HCT can be safely performed in myeloma patients 75 and older and is associated with encouraging response rates.